Topical valproic acid increases the hair count in male patients with androgenetic alopecia: A randomized, comparative, clinical feasibility study using phototrichogram analysis

Journal of Dermatology

Volumn 41, Issue 4, 2014, Pages 285-291

  Jo, Seong Jin ^a   Shin, Hyoseung ^a   Park, Young Woon ^a   Paik, Seung Hwan ^a   Park, Won Seok ^b   Jeong, Yeon Su ^b   Shin, Hong Ju ^b   Kwon, Ohsang ^a  

^a Seoul National University   (South Korea)

^b Skin Research Institute Amorepacific RandD Center   (South Korea)

Author keywords

androgenetic alopecia; glycogen synthase kinase 3; hair; valproic acid; Wnt; catenin

Indexed keywords

PLACEBO; VALPROIC ACID; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; HAIR ANALYSIS; HAIR GROWTH; HAIR LOSS; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; MALE TYPE ALOPECIA; MEDICATION COMPLIANCE; PHOTOTRICHOGRAM ANALYSIS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TOPICAL TREATMENT; TREATMENT OUTCOME; ALOPECIA; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HAIR; MIDDLE AGED; PATHOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; ALOPECIA; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; HAIR; HUMANS; MALE; MIDDLE AGED; VALPROIC ACID;

EID: 84897544427     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12422     Document Type: Article

References (42)

1. Norwood OT,. Male pattern baldness: classification and incidence. South Med J 1975; 68: 1359-1365.
2. Cash TF,. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 1992; 26: 926-931.
3. Hibberts N,. Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J Endocrinol 1998; 156: 59-65.
4. Eun HC, Kwon OS, Yeon JH, et al,. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol 2010; 63: 252-258.
5. Kwack MH, Sung YK, Chung EJ, et al,. Dihydrotestosterone-inducible dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes. J Invest Dermatol 2008; 128: 262-269.
6. Kitagawa T, Matsuda K, Inui S, et al,. Keratinocyte growth inhibition through the modification of Wnt signaling by androgen in balding dermal papilla cells. J Clin Endocrinol Metab 2009; 94: 1288-1294.
7. Leirõs G, Attorresi A, Balañá M,. Hair follicle stem cell differentiation is inhibited through a cross talk between Wnt/β-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Br J Dermatol 2012; 166: 1035-1042.
8. Millar SE,. Molecular mechanisms regulating hair follicle development. J Invest Dermatol 2002; 118: 216-225.
9. Shimizu H, Morgan BA,. Wnt signaling through the β-catenin pathway is sufficient to maintain, but not restore, anagen-phase characteristics of dermal papilla cells. J Invest Dermatol 2004; 122: 239-245.
10. Yamauchi K, Kurosaka A,. Inhibition of glycogen synthase kinase-3 enhances the expression of alkaline phosphatase and insulin-like growth factor-1 in human primary dermal papilla cell culture and maintains mouse hair bulbs in organ culture. Arch Dermatol Res 2009; 301: 357-365.
11. Johannessen CU,. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000; 37: 103-110.
12. Perucca E,. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714.
13. Wiltse J,. Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin-developmental effects of valproic acid. Crit Rev Toxicol 2005; 35: 727-738.
14. Werstuck GH, Kim AJ, Brenstrum T, Ohnmacht SA, Panna E, Capretta A,. Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds. Bioorg Med Chem Lett 2004; 14: 5465-5467.
15. Rosenberg G,. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 2007; 64: 2090-2103.
16. Hall AC, Brennan A, Goold RG, et al,. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci 2002; 20: 257-270.
17. Jo SJ, Choi SJ, Yoon SY, et al,. Valproic acid promotes human hair growth in in vitro culture model. J Dermatol Sci 2013; 72: 16-24.
18. Lee SH, Yoon J, Shin SH, et al,. Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. PLoS One 2012; 7: e34152.
19. Gurvich N,. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004; 64: 1079-1086.
20. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS,. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
21. Blaheta RA, Cinatl J Jr,. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002; 22: 492-511.
22. Stoll C, Audeoud F, Gaugler C, Bernardin A, Messer J,. Multiple congenital malformations including generalized hypertrichosis with gum hypertrophy in a child exposed to valproic acid in utero. Genet Couns 2003; 14: 289-298.
23. Davis R, Peters DH, McTavish D,. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-372.
24. McKinney PA, Finkenbine RD, DeVane CL,. Alopecia and mood stabilizer therapy. Ann Clin Psychiatry 1996; 8: 183-185.
25. Mercke Y, Sheng H, Khan T, Lippmann S,. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000; 12: 35-42.
26. Schulpis KH, Karikas GA, Tjamouranis J, Regoutas S, Tsakiris S,. Low serum biotinidase activity in children with valproic acid monotherapy. Epilepsia 2001; 42: 1359-1362.
27. Arslan M, Vurucu S, Balamtekin N, et al,. The effects of biotin supplementation on serum and liver tissue biotinidase enzyme activity and alopecia in rats which were administrated to valproic acid. Brain Dev 2009; 31: 405-410.
28. Castro-Gago M, Gomez-Lado C, Eiris-Punal J, Diaz-Mayo I, Castineiras-Ramos DE,. Serum biotinidase activity in children treated with valproic acid and carbamazepine. J Child Neurol 2010; 25: 32-35.
29. Grier RE, Heard GS, Watkins P, Wolf B,. Low biotinidase activities in the sera of patients with impaired liver function: evidence that the liver is the source of serum biotinidase. Clin Chim Acta 1990; 186: 397-400.
30. Yilmaz Y, Tasdemir HA, Paksu MS,. The influence of valproic acid treatment on hair and serum zinc levels and serum biotinidase activity. Eur J Paediatr Neurol 2009; 13: 439-443.
31. Kaufman KD, Olsen EA, Whiting D, et al,. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39: 578-589.
32. Savin RC,. Use of topical minoxidil in the treatment of male pattern baldness. J Am Acad Dermatol 1987; 16: 696-704.
33. Courtois M, Loussouarn G, Hourseau S, Grollier JF,. Periodicity in the growth and shedding of hair. Br J Dermatol 1996; 134: 47-54.
34. Randall VA, Ebling FJ,. Seasonal changes in human hair growth. Br J Dermatol 1991; 124: 146-151.
35. Meyer S, Kuhlmann MK, Peters FT, Limbach HG, Lindinger A,. Severe valproic acid intoxication is associated with atrial tachycardia: secondary detoxication by hemoperfusion. Klin Padiatr 2005; 217: 82-85.
36. Klotz U, Schweizer C,. Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels. Int J Clin Pharmacol Ther Toxicol 1980; 18: 461-465.
37. Tsuboi R, Arano O, Nishikawa T, Yamada H, Katsuoka K,. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. J Dermatol 2009; 36: 437-446.
38. Shin HS, Won CH, Lee SH, Kwon OS, Kim KH, Eun HC,. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. Am J Clin Dermatol 2007; 8: 285-290.
39. Tsuboi R, Tanaka T, Nishikawa T, et al,. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. Eur J Dermatol 2007; 17: 37-44.
40. Olsen EA, Whiting D, Bergfeld W, et al,. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57: 767-774.
41. Olsen EA, Dunlap FE, Funicella T, et al,. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47: 377-385.
42. Leenen FH, Smith DL, Unger WP,. Topical minoxidil: cardiac effects in bald man. Br J Clin Pharmacol 1988; 26: 481-485.